KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Abbott Laboratories (ABT) Enterprise Value (2016 - 2025)

Abbott Laboratories' Enterprise Value history spans 17 years, with the latest figure at -$8.3 billion for Q4 2025.

  • For Q4 2025, Enterprise Value fell 7.35% year-over-year to -$8.3 billion; the TTM value through Dec 2025 reached -$8.3 billion, down 7.35%, while the annual FY2025 figure was -$8.3 billion, 7.35% down from the prior year.
  • Enterprise Value for Q4 2025 was -$8.3 billion at Abbott Laboratories, down from -$7.4 billion in the prior quarter.
  • Across five years, Enterprise Value topped out at -$6.4 billion in Q1 2024 and bottomed at -$10.0 billion in Q4 2021.
  • The 5-year median for Enterprise Value is -$7.9 billion (2022), against an average of -$8.1 billion.
  • The largest annual shift saw Enterprise Value crashed 135.5% in 2021 before it skyrocketed 31.06% in 2024.
  • A 5-year view of Enterprise Value shows it stood at -$10.0 billion in 2021, then increased by 0.76% to -$10.0 billion in 2022, then grew by 29.1% to -$7.1 billion in 2023, then fell by 9.57% to -$7.7 billion in 2024, then decreased by 7.35% to -$8.3 billion in 2025.
  • Per Business Quant, the three most recent readings for ABT's Enterprise Value are -$8.3 billion (Q4 2025), -$7.4 billion (Q3 2025), and -$7.0 billion (Q2 2025).